Physician profile
Nananamibia Duffy
NPI 1700918950
$9,215.71
in general payments reported to CMS, 2019-2025
19 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $145 · 2021: $254 · 2022: $514 · 2023: $1,895 · 2024: $4,881 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,160 · Food and Beverage: $2,451 · Travel and Lodging: $1,205 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,160.00 |
| Food and Beverage | $2,450.64 |
| Travel and Lodging | $1,204.61 |
| Education | $209.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,622.77 | 2021-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,423.91 | 2022-2025 | Spevigo |
| Abbvie INC. | $586.41 | 2020-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $356.68 | 2019-2024 | Dupixent |
| Genzyme Corporation | $338.67 | 2020-2025 | |
| Ucb, INC. | $314.48 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $296.98 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $207.56 | 2024 | Vtama |
| Lilly USA, LLC | $194.81 | 2025 | Taltz, Ebglyss |
| Amgen INC. | $136.16 | 2020-2025 | Tavneos |
| Janssen Scientific Affairs, LLC | $123.75 | 2019 | |
| Incyte Corporation | $113.33 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $109.92 | 2022-2023 | Ilumya |
| Organon LLC | $99.74 | 2025 | Vtama |
| Merz North America, INC. | $87.06 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $80.89 | 2024 | Sotyktu |
| Strata Skin Sciences, INC. | $74.09 | 2024 | Xtrac |
| Prugen, INC. Pharmaceuticals | $29.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nananamibia Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.